Archives

Author's Posts

This statistic from the Centers for Disease Control and Prevention says it all: Approximately half of all American adults live with a chronic condition, and nearly one-third suffer from multiple. It’s no wonder, then, that chronic sicknesses significantly affect the American healthcare system.

Nowadays, Western medicine focuses on a disease’s specific symptoms, which mostly relieves symptoms or stops their progression. But persistent illness is a systemic problem that relates to a specific organ or several related ones.

Even if you relieve the problem, it’s only a temporary reprieve because the ailment will eventually recur and progress. Regeneration offers a means for eliminating chronic problems, preventively regenerating new cells, tissues, and even complete organs to return the body to its disease-free physiological state.

For example, let’s examine chronic atrophic gastritis. A common gastrointestinal tract illness, CAG-induced pain is often treated with tablets that neutralize or adjust the GI’s environment. The condition, however, does destroy the cells in your stomach lining and cause metaplasia, which transforms or replaces them with acid-producing versions that live in your stomach.

Through regenerative rejuvenation, the metaplasia cells could be physiologically replaced by newly regenerated cells of the proper type. Eventually, all GI cell types and distribution will be able to maintain the same normal physiological state you had when you were young.

This is just one example of how regenerative rejuvenation works and how it can reduce the increasing financial burden on this country’s healthcare system. The onus of treatment shouldn’t just fall on doctors trying to find a cure.

Looking inward can enable us to replenish what’s already there. It can be a cost-efficient and less invasive version of recuperation.

Regenerating and Revitalizing the Future of Healthcare
Regenerative properties should be of specific interest to a population that’s doing exactly what it’s supposed to: getting older.

The CDC estimates the United States spends approximately $3 trillion in healthcare each year, about 17.5 percent of the country’s GDP. Chronic illness patients aged 65 and older are up to eight times more likely to incur these costs than those younger than 45.

Regenerative medicine holds the potential to curb those costs by providing more effective and affordable long-term solutions and an improved quality of life. Using the chronic GI illness mentioned above, regenerative medicine could renew a GI tract’s compromised mucosal layer. When it’s healthy, it’s more than capable of enduring both the basic and extremely acidic damage caused by internal fluid.

As people age, the GI mucosal layer becomes thinner, which can lead to chronic conditions such as inflammatory atrophic gastritis. Rather than focus on the symptoms of these conditions, physiological regeneration can restore the thickness and sustainability of the mucosal layer, preventing symptoms from recurring.

But regeneration isn’t just confined to chronic GI issues. Skin, as an external organ, is also susceptible to chronic pathological conditions that may be reversed with regenerative medicine. Physiological regeneration of traumatized tissue can prevent scar formation and potential disability. It can also halt the need for skin grafts that can lead to everlasting healthcare costs to maintain or improve your overall quality of life.

Regeneration isn’t just about getting overall healthcare costs under control; it’s about helping people — especially the chronically ill — enjoy the health and vitality of their youth, even into their golden years.

Exploring alternative means of treatment helps make that sustained contentedness possible. The examples above are just a few of the possibilities represented by regenerative medicine’s potential when utilized by those in need.

As more and more people contract or develop chronic illnesses, options outside the traditional treatment arena need to be explored. Make regeneration one avenue you take a long look at.

World Congress of Biomedical Engineering-2017

Theme: Co-creating a New Future of Biomedicine

Time: November 9-11, 2017 Place: Xi’an, China

Dear Dr. Anand Srivastava,

We are proud to announce that The World Congress of Biomedical Engineering-2017 (WCBME-2017) with a theme of “Co-creating a New Future of Biomedicine”, will be held during 9 to 11 November, 2017, Xi’an, China. On behalf of the organizing committee, we cordially welcome you to join us as a speaker at Session 6-3: Tissue Repair and Regenerative Medicine.

WCBME-2017 features a very strong technical program, mainly focused on: Biomechanics and Mechanobiology, Biomedical Imaging, Biomaterials, Biosensors and Bioelectronics, Cell and Tissue Engineering, Nanomedicine, Biomedical Optics, and cutting-edge Biomedical Instrumentation and Devices. It aims to provide a platform for all experts from academia, industry and national labs to discuss latest hot researches and achievements. Attendees will hear world-class speakers discussing the challenges and opportunities facing the biomedical engineering field. The business & academic experts who are from home and abroad will give excellent speeches.

In addition to the dynamic scientific program, you will benefit from the wonderful experience in Xi’an, China. Xi’an is the oldest of the Four Great Ancient Capitals, having held the position under several of the most important dynasties in Chinese history. We hope you will enjoy your stay in this beautiful city with all its feature, beauty, architecture and hospitality!

PS: We expect your precious comments or suggestions on the structure of our program, as well as your reference to other speakers that will be highly appreciated. We look forward to receiving your replies on the following questions:

Do you have any suggestions about our program?

What topic would you like to talk about at the conference? Could you please forward us a speech title and a brief introduction to your topic?

I would like to invite you to review the above-referenced manuscript. To maintain our journal’s high standards we need the best reviewers, and given your expertise in this area I would greatly appreciate your contribution.

I kindly ask you to give this review invitation the same consideration that you would want one of your own manuscripts to receive. Please find the abstract of the manuscript at the end of this email.

If you are willing to review this manuscript, please click on the link below:

Please also note that authors have been invited to convert their supplementary material into a Data in Brief article (a data description article). You may notice this change alongside the revised manuscript. You do not need to review this, but may need to look at the files in order to confirm that any supporting information you requested is present there.

I look forward to receiving your response.

Kind regards,

Julius Cruse
Editor-in-Chief
Experimental and Molecular Pathology

Abstract:

To investigate epithelial membrane protein-1 (EMP1) gene function in Head and Neck Squamous Cell Carcinoma (HNSCC) tumorigenesis and development. We first used GEO dataset to analyze the EMP1 gene expression in HNSCC. Second, we investigated the EMP1 protein expression in tissue microassay to analyze the relationship between EMP1 protein expression and TNM stage. Third, the co-expression genes data of EMP1 were extracted from Cancer Cell Line Encyclopedia database(CCLE database) , and their correlation were analyzed in The Cancer Genome Atlas HNSCC database(TCGA HNSCC database). Next, the GO (Gene Ontology Analysis) and KEGG Pathway enrichment analysis were carried out. Finally, we overexpressed the EMP1 in HNSCC cell line Cal-27, protein expression were analyzed by Western blot respectively as well as cell viability and migration were evaluated by Cell Counting Kit-8 (CCK-8) and transwell chamber assay. Analysis of GEO dataset concluded that EMP1 gene is down-regulated in HNSCC tumor tissues compared with normal tissues (P<0.05). There was no statistically significant difference of EMP1 gene expression between different T-stage and N-stage tumor tissues (P>0.05). The results of TMA showed that EMP1 protein expression in tumor was lower than that in normal tissue (P<0.05). Expression of EMP1 protein was not correlated with TNM stage of HNSCC. In addition, The Cal-27 overexpressed EMP1 significantly decreased cell viability and the invasion significantly reduced (P<0.05). After EMP1 overexpression ITGA3 and EPHA2 genes were significantly up-regulated, while ANXA1 gene was significantly down-regulated. Our data demonstrated that EMP1 gene down-regulation involved in the HNSCC tumorigenesis and development. It may serve as a novel biomarker for prognostic evaluation of patients with HNSCC.

Free access to ScienceDirect and Scopus

To assist you with reviewing this manuscript it is our pleasure to offer you 30 days of free access to ScienceDirect and Scopus. Your complimentary access can be accessed at any time within 6 months of the day you accept this review invitation and will ensure that you can access ScienceDirect and Scopus both from home and via your institute. Just click on the ‘Go to Scopus’ tab on your main menu.

Have questions or need assistance?

For more information on the review process, please visit the Reviewer Support site.

For further assistance, please visit our Customer Support site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

Journal of Stem Cell Research & Therapeutics (2475-5540)

At first, I sincerely apologize if am disturbing you in your hectic schedule.

We are glad to let you know that Journal of Stem Cell Research & Therapeutics (2475-5540) have successfully released the former issues in 2016.

Moreover we are running with Volume 2 issue 2 and we are in need of one article to accomplish this issue. In fact we have gone through your eminent articles in online and my desire is to fulfill the issue with your article.

Hence I humbly request you to submit your manuscript (Review/Mini review/Case Report) at the earliest. Your prompt submission will help me to release the issue in time and will impact my ranking too.

Hope you will understand us and look forward to receive your manuscript as early as possible.